Keros Therapeutics Inc. (KROS)
NASDAQ: KROS
· Real-Time Price · USD
14.46
0.04 (0.28%)
At close: Aug 15, 2025, 3:59 PM
14.08
-2.66%
After-hours: Aug 15, 2025, 05:42 PM EDT
Keros Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -30.7M | 148.45M | -46.03M | -52.96M | -45.26M | -43.11M | -40.24M | -39.44M | -37.51M | -35.8M | -29.72M | -23.51M | -27.27M | -24.19M | -6.94M | -20.3M | -15.62M | -15.88M |
Depreciation & Amortization | 370K | 344K | 332K | 314K | 306K | 277K | 247K | 210K | 191K | 167K | 127K | 126K | 308K | 113K | 104K | 103K | 91K | 80K |
Stock-Based Compensation | 8.54M | 8.86M | 9.2M | 8.82M | 8.79M | 8.07M | 7.32M | 8.71M | 7.04M | 5.69M | 4.75M | 4.75M | 4.79M | 4.39M | 3.29M | 3.08M | 2.85M | 2.49M |
Other Working Capital | -8.53M | 15.46M | -7.44M | 14.74M | -5.82M | -10.07M | 129K | -3.62M | -343K | -6.13M | 2.48M | -1.2M | -5.29M | 723K | -17.78M | 1.82M | -3.44M | 1.85M |
Other Non-Cash Items | 581K | 584K | 572K | 563K | 7.91M | 9.02M | 335K | 341K | 354K | 526K | 322K | 222K | 206K | 203K | 907K | -589K | 103K | 99K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 26K | n/a | 20K | n/a |
Change in Working Capital | -8.42M | 2.93M | -10.09M | 12.76M | -3.98M | -10.13M | 6.88M | -3.8M | -913K | -4.81M | 3.08M | -6.2M | -632K | 18.05M | -16.96M | 3.26M | -5.08M | 2.71M |
Operating Cash Flow | -29.62M | 161.17M | -46.01M | -30.5M | -39.8M | -44.56M | -25.46M | -33.98M | -30.83M | -34.23M | -21.44M | -24.6M | -22.59M | -1.43M | -19.57M | -14.44M | -17.64M | -10.51M |
Capital Expenditures | -720K | -565K | -289K | -386K | -310K | -946K | -541K | -550K | -311K | -1.06M | -351K | -176K | -567K | -147K | -159K | -145K | -510K | -210K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -720K | -565K | -289K | -386K | -310K | -946K | -541K | -550K | -311K | -1.06M | -351K | -176K | -567K | -147K | -159K | -145K | -510K | -210K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | 2.44M | 878K | 2.9M | 5.46M | 737K | 284K | 1.74M | 370K | 15K | 96K | 502K | 118K | 245K | 35K | 57K | 42K |
Financial Cash Flow | 17K | 4K | 75.54M | 155.94M | 3.53M | 156.8M | 69.25M | 284K | 1.74M | 107.68M | 61.42M | 48.58M | 10.19M | 118K | 28.42M | 35K | 57K | 42K |
Net Cash Flow | -30.33M | 160.61M | 29.25M | 125.06M | -36.58M | 111.3M | 43.25M | -34.25M | -29.4M | 72.38M | 39.62M | 23.8M | -12.96M | -1.46M | 8.69M | -14.55M | -18.09M | -10.67M |
Free Cash Flow | -30.34M | 160.61M | -46.3M | -30.89M | -40.11M | -45.51M | -26M | -34.53M | -31.14M | -35.3M | -21.79M | -24.78M | -23.16M | -1.57M | -19.72M | -14.59M | -18.15M | -10.71M |